کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5657668 | 1407407 | 2017 | 15 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
DAAOBIIP-10HBsAgHBeAgCHCSVRHCC - HCCHepatitis B surface antigen - آنتی ژن سطحی هپاتیت BTherapy - درمانRisk factor - عامل خطرdirect-acting antiviral agent - عامل ضد ویروسی مستقیم عملPrognostic factor - عامل پیش آگهیCoinfection - عفونتOccult HBV infection - عفونت HBV غیر عادیHepatitis B e antigen - هپاتیت B آنتی ژنchronic hepatitis C - هپاتیت C مزمنHBV - هپاتیت بHCV - هپاتیت سیHepatitis C virus - هپاتیت سیhepatitis B virus - ویروس هپاتیت بیSustained virologic response - پاسخ پایدار ویروسیHepatocellular carcinoma - کارسینوم هپاتوسلولار(کارسینوم سلولهای استخوانی)
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
بیماریهای گوارشی
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Hepatitis due to reactivation of hepatitis B virus (HBV) has been reported in patients treated with direct-acting antiviral (DAA) agents for chronic hepatitis C virus infection. We performed an observational study to determine the incidence of and factors associated with hepatitis in 327 patients receiving pan-oral DAA agents for HCV infections in areas endemic for HBV in China. Ten patients were positive for hepatitis B surface antigen (HBsAg), and 124 patients had occult HBV infection. HBV reactivation was determined by measuring HBV DNA and HBsAg status in serial serum samples collected every 2 weeks during DAA treatment and then every 4 weeks after treatment until week 12. In the total study population, 10 patients (3.1%) had hepatitis; 3 cases were associated with HBV reactivation (1 case not in the icteric phase, 1 case in the icteric phase, and 1 case with liver failure) and 7 from other causes. Testing positive for HBsAg before DAA treatment was a strong risk factor for developing hepatitis during treatment (hazard ratio, 15.0; P < .001).
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Clinical Gastroenterology and Hepatology - Volume 15, Issue 1, January 2017, Pages 132-136
Journal: Clinical Gastroenterology and Hepatology - Volume 15, Issue 1, January 2017, Pages 132-136
نویسندگان
Cheng Wang, Dong Ji, Jing Chen, Qing Shao, Bing Li, Jialiang Liu, Vanessa Wu, April Wong, Yudong Wang, Xiaoyong Zhang, Lei Lu, Chris Wong, Stella Tsang, Zheng Zhang, Jian Sun, Jinlin Hou, Guofeng Chen, George Lau,